Brokerages Set Insulet Corporation (NASDAQ:PODD) PT at $379.10

Shares of Insulet Corporation (NASDAQ:PODD) have been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $379.10.

A number of brokerages have weighed in on PODD. Jefferies Financial Group lifted their target price on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Raymond James Financial raised their price objective on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. The Goldman Sachs Group reiterated a “buy” rating and issued a $365.00 price objective on shares of Insulet in a research note on Friday, January 9th. Canaccord Genuity Group boosted their target price on shares of Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th.

Insulet Stock Down 3.0%

Shares of NASDAQ PODD opened at $271.57 on Friday. The company has a market capitalization of $19.10 billion, a P/E ratio of 78.72, a price-to-earnings-growth ratio of 1.51 and a beta of 1.40. Insulet has a 52-week low of $230.05 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The company’s 50 day moving average price is $298.48 and its 200-day moving average price is $310.34.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter in the prior year, the firm posted $1.08 earnings per share. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. Equities analysts forecast that Insulet will post 3.92 earnings per share for the current year.

Institutional Trading of Insulet

Several large investors have recently made changes to their positions in PODD. True Wealth Design LLC boosted its holdings in Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 72 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares during the period. Trust Co. of Toledo NA OH acquired a new position in shares of Insulet during the second quarter worth approximately $35,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares in the last quarter. Finally, Quent Capital LLC acquired a new stake in Insulet in the 3rd quarter valued at $49,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.